Discussion
Up to four years after a single dose of the experimental gene therapy ifezuntirgene inilparvovec (formerly AMT-130), people with Huntington’s disease who received the high dose showed slower disease progression than would be expected without treatment. That’s according to data from two long-term Phase 1/2 clinical trials, one…